Mutation News and Research

RSS

Cancer research leaders announce the opening of ICGC-TCGA-DREAM SMC Challenge

Cancer research leaders from the Ontario Institute for Cancer Research and the University of California, Santa Cruz, in collaboration with Sage Bionetworks and IBM's DREAM, will announce tomorrow the opening of the ICGC-TCGA-DREAM Somatic Mutation Calling Challenge at the Sixth Annual RECOMB/ISCB conference.

8 Nov 2013

Findings raise prospects for new therapies to protect heart from progressive disease

Some of the most commonly prescribed drugs for the treatment of heart failure are beta-blockers and nitrates, which help to relax blood vessels and decrease the heart's workload. The drugs were thought to produce those effects through distinct molecular pathways, but according to a new study led by scientists at Temple University School of Medicine, both types of drugs may help the failing heart by counteracting the effects of an enzyme known as GRK2.

8 Nov 2013

Brain & Behavior Research Foundation announces recipients of NARSAD Investigator Grants

The Brain & Behavior Research Foundation (formerly known as NARSAD, the National Alliance for Research on Schizophrenia and Depression), under the direction of Dr. Jeffrey Borenstein, President & CEO, has announced the latest recipients of its NARSAD Distinguished Investigator Grants.

8 Nov 2013

Researchers identify enzymes that are crucial for growth of cancers with genetic aberrations in p53

The most frequently mutated gene across all types of cancers is a gene called p53. Unfortunately it has been difficult to directly target this gene with drugs. Now a multi-institutional research team, led by Dr. Lewis Cantley and investigators at Weill Cornell Medical College, has identified a family of enzymes they say is crucial for the growth of cancers that have genetic aberrations in p53.

8 Nov 2013

Researchers discover relationship between TGFb signalling pathways and CXCR4 in HCC

Researchers from the Biological clues of the invasive and metastatic phenotype group of the Bellvitge Biomedical Research Institute (IDIBELL) led by Isabel Fabregat have discovered the relationship between the TGFb signalling pathways and CXCR4 in hepatocellular carcinoma (HCC) .

7 Nov 2013

Advanced prostate cancer therapies: an interview with Dr. Nancy Dawson, Lombardi Comprehensive Cancer Center

The prostate gland produces part of the seminal fluid that protects sperm. It is located in front of the rectum and under the bladder, and surrounds the urethra, the tube through which urine flows from the bladder to and out of the penis.

6 Nov 2013

New drug combination therapy effectively kills cancer cells

Results from a recent preclinical study have shown that a new drug combination therapy being developed at Virginia Commonwealth University Massey Cancer Center effectively killed colon, liver, lung, kidney, breast and brain cancer cells while having little effect on noncancerous cells. The results lay the foundation for researchers to plan a future phase 1 clinical trial to test the safety of the therapy in a small group of patients.

6 Nov 2013

Scientists investigate combined action of two different compounds against CML

Currently no treatment option is available for five percent of patients suffering from chronic myelogenous leukemia, since they have developed resistance to conventional medications. Prof. Stephan Grzesiek's group at the Biozentrum of the University of Basel, in collaboration with Dr. Wolfgang Jahnke and colleagues from Novartis, has investigated the combined action of two different compounds against this form of leukemia.

6 Nov 2013

Endocrine Society announces winners of organization's prestigious 2014 Laureate Awards

The Endocrine Society today announced it has selected 15 accomplished endocrinologists as winners of the organization's prestigious 2014 Laureate Awards.

5 Nov 2013

AMP 2013 to focus on genomics, proteomics, informatics, reimbursement and optimization of patient care

AMP will host its largest ever annual meeting next week with an expected attendance of more than 1,700 molecular diagnostic professionals plus 1,300 representatives from more than 180 exhibiting companies. With more than 25 hours of educational sessions and 350 poster presentations, the AMP 2013 Annual Meeting is the premier source for educational information on all things molecular.

5 Nov 2013

Gene mutated in rare hereditary disorder also prevents mTORC1 pathway activation

Whitehead Institute scientists report that the gene mutated in the rare hereditary disorder known as Birt-Hogg-Dub- cancer syndrome also prevents activation of mTORC1, a critical nutrient-sensing and growth-regulating cellular pathway.

5 Nov 2013

Research findings could offer new insights into how defective cells can multiply in diseases

A rudimentary form of life that is found in some of the harshest environments on earth is able to sidestep normal replication processes and reproduce by the back door, researchers at The University of Nottingham have found.

5 Nov 2013

Researchers identify factor that promotes metastasis of colon tumors

Tumors become highly malignant when they acquire the ability to colonize other tissues and form metastases. Researchers at Ludwig-Maximilians-Universitaet (LMU) in Munich have identified a factor that promotes metastasis of colon tumors - and presents a possible target for therapy.

5 Nov 2013

Gene sequencing reveals mutations in estrogen receptor

Researchers at the University of Michigan Comprehensive Cancer Center have identified a type of mutation that develops after breast cancer patients take anti-estrogen therapies. The mutations explain one reason why patients often become resistant to this therapy.

4 Nov 2013

LMU researchers identify a factor that promotes metastasis of colon tumors

Tumors become highly malignant when they acquire the ability to colonize other tissues and form metastases. Researchers at Ludwig-Maximilians-Universitaet in Munich have identified a factor that promotes metastasis of colon tumors - and presents a possible target for therapy.

4 Nov 2013

Boehringer Ingelheim's Phase II trial of interferon-free hepatitis C treatment shows promising results

Interim data presented today show that all patients (13/13) who reached their 4-week post-treatment follow-up have undetectable levels of hepatitis C virus (SVR4) after completing a 12-week regimen of faldaprevir, deleobuvir, PPI-668 and ribavirin.

4 Nov 2013

Patients with mutation in gene encoding CX3CR1 at higher risk of candidiasis

Candida albicans is one of the leading causes of hospital-acquired infections in immune compromised patients. The risk of both developing candidiasis and the clinical outcome of infection is variable among patients, and the host-dependent factors that contribute to patient susceptibility to C. albicans infection are poorly understood.

4 Nov 2013

Mutation News and Research

Cancer research leaders announce the opening of ICGC-TCGA-DREAM SMC Challenge

Findings raise prospects for new therapies to protect heart from progressive disease

Brain & Behavior Research Foundation announces recipients of NARSAD Investigator Grants

Researchers identify enzymes that are crucial for growth of cancers with genetic aberrations in p53

Researchers discover relationship between TGFb signalling pathways and CXCR4 in HCC

Advanced prostate cancer therapies: an interview with Dr. Nancy Dawson, Lombardi Comprehensive Cancer Center

New drug combination therapy effectively kills cancer cells

Scientists investigate combined action of two different compounds against CML

Endocrine Society announces winners of organization's prestigious 2014 Laureate Awards

AMP 2013 to focus on genomics, proteomics, informatics, reimbursement and optimization of patient care

Gene mutated in rare hereditary disorder also prevents mTORC1 pathway activation

Research findings could offer new insights into how defective cells can multiply in diseases

Researchers identify factor that promotes metastasis of colon tumors

Gene sequencing reveals mutations in estrogen receptor

LMU researchers identify a factor that promotes metastasis of colon tumors

Boehringer Ingelheim's Phase II trial of interferon-free hepatitis C treatment shows promising results

Patients with mutation in gene encoding CX3CR1 at higher risk of candidiasis

McMaster University researchers discover how metformin drug works on fat in the liver

Toxicity limits benefits of bevacizumab–erlotinib NSCLC maintenance therapy

Array BioPharma reports net loss of $0.13 per share for first quarter of fiscal 2014

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence

Latest News